Search results for "Vasodilators"

showing 3 items of 3 documents

Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching

2017

Introduction Current treatment with vasodilators for pulmonary hypertension associated with respiratory diseases is limited by their inhibitory effect on hypoxic pulmonary vasoconstriction (HPV) and uncoupling effects on ventilation-perfusion (V'/Q'). Hypoxia is also a well-known modulator of the nitric oxide (NO) pathway, and may therefore differentially affect the responses to phosphodiesterase 5 (PDE5) inhibitors and soluble guanylyl cyclase (sGC) stimulators. So far, the effects of the sGC stimulator riociguat on HPV have been poorly characterized. Materials and methods Contraction was recorded in pulmonary arteries (PA) in a wire myograph. Anesthetized rats were catheterized to record …

MaleAnoxemiaPulmonologyPulmonary FibrosisVasodilator Agentslcsh:MedicineVasodilation030204 cardiovascular system & hematologyPharmacologyVascular Medicinechemistry.chemical_compound0302 clinical medicineSoluble Guanylyl CyclaseHypoxic pulmonary vasoconstrictionPulmonary fibrosisMedicine and Health SciencesPulmonary Arterieslcsh:ScienceHypoxiaMultidisciplinaryVasodilatorsDrugsRespiratory organs diseasesArteriesMiddle AgedChemistryPhysical Sciencescardiovascular systemFemalemedicine.symptomAnatomyMedicamentsmedicine.drugResearch ArticleChemical Elementsinorganic chemicalsSildenafilHypertension PulmonaryChronic Obstructive Pulmonary DiseaseEnzyme ActivatorsIn Vitro TechniquesPulmonary ArteryRiociguatSildenafil CitrateMalalties de l'aparell respiratori03 medical and health sciencesMedical HypoxiamedicineVentilation-Perfusion RatioAnimalsHumansRats WistarAgedPharmacologybusiness.industrylcsh:RAnoxèmiaBiology and Life SciencesHypoxia (medical)Phosphodiesterase 5 Inhibitorsmedicine.diseasePulmonary hypertensionFibrosisRatsOxygenDisease Models AnimalPyrimidines030228 respiratory systemchemistryVasoconstrictionCardiovascular AnatomyPyrazolesBlood Vesselslcsh:QSoluble guanylyl cyclasebusinessDevelopmental Biology
researchProduct

Non-occlusive mesenteric Ischemia (NOMI) in Parkinson’s disease: Case report

2017

Non-occlusive mesenteric ischemia (NOMI) is a severe pathological condition characterized by signs and symptoms of bowel obstruction, intestinal necrosis resulting from acute and/or chronic inadequate blood perfusion, in the absence of an organic vascular obstruction detectable by imaging techniques. A 64 years old man case with a history of Parkinson’s disease in high-functioning levodopa treatment is presented. Clinical and radiological signs of intestinal obstruction were observed. He underwent surgical operation with total colectomy and terminal ileostomy for generalized secondary peritonitis due to perforation of sigmoid colon. Ischemic pancolitis was first suspected. In third post-o…

Malemedicine.medical_specialtyPancolitisNon-occlusive mesenteric ischemia (NOMI)medicine.medical_treatmentPerforation (oil well)Intestinal necrosiurologic and male genital diseasesGastroenterologyTotal colectomyClinical PracticeIleostomymedicine.arteryInternal medicineVasodilatormedicineHumansParkinson’s diseaseSuperior mesenteric arteryVeinBowel obstruction; Intestinal necrosis; Non-occlusive mesenteric ischemia (NOMI); Parkinson’s disease; Total colectomy; Vasodilators; Surgerybusiness.industrySigmoid colonParkinson DiseaseMiddle Agedmedicine.diseaseSurgeryBowel obstructionSettore MED/18 - Chirurgia Generalemedicine.anatomical_structureMesenteric ischemiaMesenteric IschemiaSurgerymedicine.symptombusinessTomography X-Ray ComputedIntestinal ObstructionBowel obstruction
researchProduct

Síndrome hepatopulmonar en paciente con adenocarcinoma de colon con metástasis hepáticas y sin hepatopatía crónica conocida

2006

El sindrome hepatopulmonar comprende una triada clinica caracterizada por desoxigenacion arterial, dilataciones vasculares intrapulmonares y hepatopatia. Se han descrito tanto casos agudos como cronicos, y la causa mas frecuente es la cirrosis. El mecanismo fisiopatologico principal es la dilatacion de los vasos pulmonares, que produce una alteracion del intercambio gaseoso. Se ha implicado la mayor produccion pulmonar de oxido nitrico como mecanismo patogenico principal de la vasodilatacion, aunque tambien se ha relacionado el desequilibrio entre sustancias vasodilatadoras y vasoconstrictoras. Describimos un caso en el que se produjo un sindrome hepatopulmonar en un paciente afectado de un…

Pulmonary and Respiratory MedicineGynecologymedicine.medical_specialtybusiness.industrymedicinebusinessPulmonary vasodilatorsArchivos de Bronconeumología
researchProduct